# US 2019/0314408 A1 · Use of somatic stem cells for reducing il-6 level

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314408 A1
- Document ID: US20190314408A1
- Status: Published application
- Kind: A1
- Application number: 16/473,217
- Filed: 2017-12-21
- Published: 2019-10-17
- Earliest claimed: 2016-12-23
- Assignees: StemBios Technologies, Inc.
- Applicants: StemBios Technologies, Inc.
- Inventors: James Wang
- Web page: https://patentgrep.com/patent/US20190314408A1

## CPC

- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/19: Platelets; Megacaryocytes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/5412: {IL-6}
- C12N 5/0644: {Platelets; Megakaryocytes}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2501/2306: Interleukin-6 (IL-6)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of decreasing IL-6 level in a subject, comprising: identifying a subject in need thereof; and administering to the subject a composition that contains small cells that are greater than 2 micrometer s and less than 6 micrometer s in size; wherein the small cells include somatic stem cells that are (i) pluripotent; and (i) CD349(+), CD9(−), Oct4(+), Nanog(−), Lgr5(+), CD66e(+), CD133(+), or CD34(+).

## Claims

### Claim 1

A method of decreasing IL-6 level in a subject, comprising:
identifying a subject in need thereof; and
administering to the subject a composition that contains small cells that are greater than 2 micrometer s and less than 6 micrometer s in size;
wherein the small cells include somatic stem cells that are (i) pluripotent; and (i) CD349(+), CD9(+), Oct4(+), Nanog(+), Lgr5(+), CD66e(+), CD133(+), or CD34(+).

### Claim 2 (depends on 1)

The method of claim 1, wherein the identifying step includes detecting an increased Il-6 level, as compared to a control level, in a biological sample obtained from the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the biological sample is a blood sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has a condition associated with an increased IL-6 level or condition that can be treated by an IL-6 antagonist.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject has type I diabetes.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1-5, wherein the small cells further include platelets.

### Claim 7 (depends on 6)

The method of claim 6, wherein, 75% to 85% of the small cells are the platelets and 20% to 25% of the small cells are the somatic stem cells.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition contains 10 million to 500 million of the somatic stem cells.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition is prepared by a process that includes:
providing a mixture that contains a blood sample obtained from the subject or a donor subject and a divalent cation chelating agent;
storing the mixture at a temperature between 2° C. and 12° C. for 3 to 72 hours, whereby the mixture separates into an upper layer and a lower layer, wherein the upper layer contains the population of small cells; and
collecting the upper layer, whereby the composition is prepared.

### Claim 10 (depends on 9)

The method of claim 9, wherein the divalent cation chelating agent is EDTA.

### Claim 11 (depends on 10)

The method of claim 10, wherein 1.5 to 2.0 mg of divalent cation chelating agent per millimeter of the blood sample is mixed with the blood sample to obtain the mixture.

### Claim 12 (depends on 10)

The method of claim 10, wherein, prior to obtaining the blood sample, an action for increasing stem cell number is performed on the subject or donor subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the action is administration of an effective amount of fucoidan or a granulocyte-colony stimulating factor.

### Claim 14 (depends on 10)

The method of claim 10, wherein the process for preparing the composition further includes, after collecting the upper layer, adding a pharmaceutically acceptable excipient to the collected upper layer.

### Claim 15 (depends on 10)

The method of claim 10, wherein the process for preparing the composition further includes, after collecting the upper layer, centrifuging the upper layer to obtain a cell pellet.

### Claim 16 (depends on 15)

The method of claim 15, wherein the process for preparing the composition further includes washing the pellet and suspending the pellet in a pharmaceutically acceptable excipient.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the pharmaceutically acceptable excipient is free of divalent ions.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pharmaceutically acceptable excipient is a saline solution.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any of claims 1-18, wherein the composition is administered intravenously.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any of claims 1-19, further comprising, after the administering step, detecting an IL-6 level in a biological sample obtained from the subject after the administering step.
